Company Description

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States.

It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.

The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021.

Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

Aclarion, Inc.

Country	United States
Founded	2008
IPO Date	Apr 22, 2022
Industry	Health Information Services
Sector	Healthcare
Employees	6
CEO	Brent Ness

Contact Details

Address: 8181 Arista Place, Suite 100 Broomfield, Colorado 80021 United States
Phone	833 275 2266
Website	aclarion.com

Stock Details

Ticker Symbol	ACON
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$4.35
CIK Code	0001635077
CUSIP Number	655187102
ISIN Number	US6551872012
Employer ID	47-3324725
SIC Code	8071

Key Executives

Name	Position
Brent Ness	Chief Executive Officer, President and Director
Dr. Jeffrey John Thramann M.D.	Executive Chairman
John Lorbiecki	Chief Financial Officer
Ryan Bond	Chief Strategy Officer

Latest SEC Filings

Date	Type	Title
Nov 14, 2024	10-Q	Quarterly Report
Nov 13, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024	EFFECT	Notice of Effectiveness
Nov 8, 2024	424B3	Prospectus
Nov 5, 2024	424B3	Prospectus
Nov 5, 2024	424B3	Prospectus
Nov 4, 2024	EFFECT	Notice of Effectiveness
Nov 4, 2024	S-3	Registration statement under Securities Act of 1933
Oct 25, 2024	S-1	General form for registration of securities under the Securities Act of 1933
Oct 24, 2024	EFFECT	Notice of Effectiveness

View All SEC Filings